Carl Hartman, MD
Ophthalmology · Long Beach, CANPI 1629052527
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), consulting fees and entertainment — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Rxsight Inc at 40.7% of the total. 2025 is the largest year on record at $914, 3.6 times the $254 reported in 2019.
Across 46 payments — averaging $35.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$660
- Johnson & Johnson Surgical Vision, Inc.$191
- AbbVie$110
- Optos, Inc.$93
- Sun Pharmaceutical Industries Inc.$87
- Alcon$82
- plus $398 from 11 others
Across 58 payments — averaging $12,311 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$714K
What the payments were for
- Consulting fees$57836%
- Speaking & faculty fees$262%
- Food & beverage$90656%
- Gifts$191%
- Entertainment$936%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 7 | $660 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $191 |
| AbbVie(2 entities) | 5 | $110 |
| Optos, Inc. | 2 | $93 |
| Sun Pharmaceutical Industries Inc. | 4 | $87 |
| Alcon | 3 | $82 |
| Nova Eye, Inc. | 2 | $81 |
| Bausch & Lomb Americas Inc. | 3 | $60 |
| Glaukos Corporation | 1 | $56 |
| Sight Sciences, Inc. | 3 | $52 |
| NEW World Medical,inc. | 2 | $34 |
| Thea Pharma Inc. | 1 | $22 |
| Akorn, Inc. | 1 | $21 |
| Harrow Eye, LLC | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,621 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 16 | $30,197 |
| RestasisCyclosporine | 11 | $18,079 |
| LumiganBimatoprost | 20 | $10,491 |
| VyzultaLatanoprostene Bunod | 13 | $9,550 |
| Prednisolone Acetate | 240 | $8,908 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $6,365 |
| Latanoprost | 390 | $5,435 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 184 | $4,321 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $3,690 |
| Ketorolac Tromethamine | 184 | $3,290 |
| Ofloxacin | 191 | $2,805 |
| Travoprost | 12 | $2,582 |
| Brimonidine Tartrate | 75 | $1,303 |
| Timolol Maleate | 55 | $660 |
| Dorzolamide Hcl | 16 | $638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $60 | $39,74729 claims |
| AbbVieRestasis, Lumigan | $110 | $28,56931 claims |
| AlconSimbrinza | $82 | $6,36515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Dan TranLong Beach$232K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.